Cytek Biosciences Q3 2026 Results: Net Loss of $6.1M, Loss Widens
Cytek Biosciences reported a net loss of $37.1 million for the nine months ended September 30, 2026, compared to a $22.5 million loss in the prior year period, despite a 4% increase in total revenue to $145.5 million. The increased loss was primarily driven by higher general and administrative expenses and a significant decrease in other income compared to 2025.
- Key figure
- Net loss $6.1M